Primary diagnosis / Age at primary diagnosis (years) / Treatment for childhood cancer / CRT completion to SN (years) / Age at SN (years) / Location of Tumor / Maximum size of SN (cm) / Specific Localizing Symptoms/ Signs of SN / SN Follow-up
Chemotherapy, cumulative dose (mg/m2) / CRT Dose (cGy) / Age at CRT (years)
ALL / 1.6 / Ara-C IT (766), Ara-C IV (10,498), CTX (7,392), DNR (51), High Dose MTX IV (7,000), HC (511), L-ASP (60,000), MTX IM (621), MTX IT (255), MTX IV (456), PRED, VCR (57), VM-26 (5357), VP-16 (7392), 6-MP / 2400 / 12.7 / 22.8 / 25.5 / High post L frontal / 0.9 / None / Serial imaging
ALL / 2.1 / Ara-C (8,959), L-ASP (77,759), MTX IT (381), MTX PO (4,376), PRED, VCR (5), VM-26 (4,921), 6-MP / 2400 / 2.4 / 30.3 / 33.8 / R parietal (small portion invaded SSS) / 5.4 / None / Surgical resection
(WHO Grade 2 meningioma), Gamma knife
ALL / 2.4 / CTX (28024), DNR (176), MTX IT (61), MTX IV (2793), PRED, VCR (82), 6-MP (3000), 6-MP (PO, NA) / 2520 / 3.0 / 41.7 / 46.8 / L frontal
Posterior aspect of SSS
Midportion of falx cerebri / 2.3
8.5
2.2 / None / Serial imaging
ALL / 2.4 / ADR (185), Ara-C IV (2,730), CTX (4,174), L-ASP IV (40,345), MTX IT (202), MTX PO (1,985), PRED, VCR (7), VM-26 (1,365), 6-MP / 1800 / 3.4 / 30.6 / 33.2 / R frontal
Inferior to R gyrus rectus / 0.4
0.8 / None / Serial imaging
ALL / 3.1 / Ara-C (1,200), CTX (900), DNR (151), Erwinia (50,000), L-ASP (20,000), MTX IT (61), MTX IV (2,544), PRED, VCR (14), VM-26 (693), 6-MP / 2400 / 4.8 / 32.9 / 36.2 / Craniocervical junction / 2.0 / None / Surgical resection
(meningioma – unspecified grade)
ALL / 3.3 / L-ASP (20,000), MTX IT (60), MTX IV (2,716), PRED, VCR (6), 6-MP / 2400 / 6.7 / 37.0 / 40.5 / R occipital
L frontal parafalcine
Superior aspect of tentorium / 3.4
2.5
1.0 / None / Serial imaging
ALL / 4.2 / CTX (13,027), DNR (NA), MTX IT (98), MTX PO (1,302), VCR (20), 6-MP / 2991 / 4.3 / 43.5 / 47.7 / R middle cranial fossa, anterior / 3.0 / None / None
ALL / 4.3 / CTX (13,476), MTX (1,347), PRED, VCR (64), 6-MP / 1260 / 4.5 / 45.8 / 50.3 / R frontal, lateral / 1.1 / None / None
ALL / 4.3 / Ara-C (1,049) , DNR (148) , L-ASP IM (59,390), L-ASP IV (20,164), MTX IT (60), MTX IV (2,600), PRED, VM-26 (577), VCR (9), 6-MP / 2400 / 8.0 / 33.9 / 38.2 / R parieto-occipital
R occipital, medial
L posterior fossa, inferior / 2.8
1.0
1.5 / None / Surgical resection of R parieto-occipital and R occipital lesions ( WHO Grade 1 meningiomas)
ALL / 4.6 / ADR (244), CTX (7,855), DNR (103), MTX IT (146), MTX IV (2,610), MTX PO (1,741), PRED, VCR (44), 6-MP / 4400 / 15.0 / 35.3 / 40.1 / L frontal
R parietal, anteromedial / 1.8
1.1 / None / Serial imaging
ALL / 4.6 / ADR (210), Ara-C (2,721), CTX (4,100), L-ASP (39,143), MTX IT (191), MTX PO (1,881), PRED, VCR (6), VM-26 (1,361), 6-MP / 1800 / 11.8 / 31.3 / 35.9 / R frontal parasagittal / 1.5 / None / Serial imaging
ALL / 4.8 / ACT-D (5), Ara-C IT (96), Ara-C IV (6,485), CTX (7,869), DNR (127), Erwinia (49,897), HC (64), L-ASP IM (98,627), L-ASP IV (40,000), MTX IT (80), MTX IV (2,746), PRED, VCR (59), VM-26 (2,502), VP-16 (6,783), 6-MP / 2400 / 4.7 / 32.5 / 37.4 / L frontal / 2.2 / None / Serial imaging
ALL / 5.8 / Ara-C IT (435), Ara-C IV (10,681), CTX (10,612), DNR (49), High Dose MTX (4,000), HC (290), L-ASP (59,121), MTX IM (1,127), MTX IT (145), PRED, VCR (58), VM-26 (5,489), VP-16 (10,612), 6-MP / 1800 / 2.7 / 24.4 / 31.5 / L frontal / 2.1 / None / Surgical resection
(WHO Grade 1 meningioma)
ALL / 6.5 / DNR (96), L-ASP (20,000), MTX IT (60), MTX IV (2,855), PRED, VCR (6), 6-MP / 2400 / 4.3 / 35.5 / 42.2 / R frontal / 2.1 / None / None
ALL / 6.6 / Ara-C IT (702), Ara-C IV (8,828), CTX (9,247), DNR (50), High Dose MTX (4,000), HC (468), L-ASP IM (58,902), MTX IM (1,040), MTX IT (234), PRED, VCR (55), VM-26 (5,446), VP-16 (9,247), 6-MP / 2400 / 7.8 / 23.0 / 30.5 / R frontal / 1.0 / None / None
ALL / 8.0 / Ara-C (1,121), CTX (2,097), DNR (261), Erwinia (50,000), L-ASP (19,882), MTX IT (60), MTX IV (1,808), PRED, VCR (22), VM-26 (658), 6-MP / 2400 / 3.4 / 32.0 / 40.1 / L frontal, high posterior / 1.3 / None / None
ALL / 10.6 / Ara-C IT (390), Ara-C IV (18,700), CTX (8,916), HC (260), L-ASP IM (89,639), L-ASP IV (78,087), MTX IT (285), MTX PO (5,221), PRED, VCR (49), VM-26 (9,910), VP-16 (8,916), 6-MP / 2400 / 6.8 / 28.1 / 39.9 / L frontal / 1.4 / None / Surgical resection
(WHO Grade 1 meningioma)
HL / 12.6 / CTX IV (11,297), CTX (3,105), PCZ (1,265), VCR (40) / 0 / - / 38.7 / 51.4 / L cerebellopontine angle / 3.4 / Tinnitus / Surgical resection (vestibular schwannoma)
ALL / 14.9 / DNR (98), L-ASP (19,752), MTX IT (48), MTX IV (2,291), PRED, VCR (5), 6-MP / 2400 / 3.2 / 34.0 / 49.0 / L parietal, adjacent to SSS
L temporal
L foramen magnum
R frontal
R posterior falx cerebri / 1.7
1.2
0.8
0.7
0.6 / None / RT to L parietal lesion presumed to be meningioma
ACT-D, dactinomycin; ADR, doxorubicin; ALL, acute lymphoblastic leukemia; Ara-C, cytarabine; CDDP, cisplatin; cGy, centigray; CRT, cranial radiation therapy; CTX, cyclophosphamide; DNR, daunorubicin; HC, hydrocortisone; HL, Hodgkin lymphoma; IM, intramuscular; IC, intracranial; IT, intrathecal; IV, intravenous; L, left; L-ASP, L-asparaginase; MB, medulloblastoma; MTX, methotrexate; NA, not available; PCZ, procarbazine; PO, oral; PRED, prednisone; R, right; RT, radiation treatment; SN, subsequent neoplasm; SSS, superior sagittal sinus; VCR, vincristine; VM-26, teniposide;VP-16, etoposide; WHO, World Health Organization; 6-MP, mercaptopurine